Bupivicaine for Hot Flashes (R01 Trial)

"Based on the criteria for admission, potential participants must be between 40 and 70 years of age."

"At present, 205 clinical trials for Bupivicaine are underway. Of these studies, 42 have advanced to Phase 3 and can be found in Germantown, Tennessee alongside 523 other sites running related experiments."

"As of now, this research study is not taking on any new participants. It was first posted in July 2018 and last updated November 2022. If you are trying to find alternative trials for hot flashes or Bupivicaine, there are presently 31 and 205 studies respectively that are accepting patients."

"This trial is not actively recruiting new patients; the post was first published on July 10, 2018 and last updated on November 1st 2022. However, if you are looking for alternative studies, there are 31 clinical trials searching for participants with hot flashes and 205 trials searching for those affected by Bupivicaine."

"This medical study is seeking 160 post-menopausal individuals aged 40 to 70, who experience 50 or more moderate-to-severe hot flashes per week and whose symptoms are unresponsive to approved oral treatments. A minimum of two weeks' worth of vasomotor symptom diary recording must be completed preceeding the SGB procedure (or sham treatment). Participants must also agree to fluoroscopy guidance for their procedure."

"Bupivicaine is a viable treatment for general surgery, lupus erythematosus cell, and ulcerative colitis."

"Our team has assessed Bupivicaine's safety to be a 2, as this Phase 2 trial includes evidence of its security but not efficacy."